Ellads
- China’s Abogen Biosciences has entered into a licensing and option agreement with Novartis (NVS) to advance RNA-encoded therapeutics, according to a statement on Friday. Abogen will receive an upfront payment of $575 million, and, if all options on all programs are exercised, Abogen is
